Significant Milestone in Zymeworks' Clinical Journey
Zymeworks Inc., a pioneering clinical-stage biotechnology firm, has reached an important milestone in its ongoing commitment to develop innovative therapies. The company, known for its robust pipeline of biotherapeutics, proudly announced the first patient dosed in its Phase 1 clinical trial evaluating ZW191, aimed at treating advanced solid tumors expressing the folate receptor-?.
Overview of the Phase 1 Clinical Trial
This groundbreaking trial will assess the safety and tolerability of ZW191, a first-in-human study that targets challenging cancers. These include advanced forms of ovarian, endometrial, and non-small cell lung cancers, conditions known for their difficulty in treatment.
Exciting Developments in Cancer Treatment
Dr. Jeff Smith, Executive Vice President and Chief Medical Officer at Zymeworks, articulated the enthusiasm surrounding this initiative. "Initiating this clinical trial represents a crucial step toward improving treatment options for patients badly affected by aggressive cancers," he stated. This trial comes on the heels of another significant progression with the Phase 1 trial of ZW171.
Mechanism of Action for ZW191
ZW191 operates as an antibody-drug conjugate designed explicitly to harness the specificity of folate receptor-?, a protein expressed on certain tumor types. With approximately 75% of high-grade serous ovarian carcinomas and around 70% of lung adenocarcinomas showcasing this receptor, ZW191 is engineered for effective internalization into the tumor cells, aiding in the elimination of cancerous cells.
Results from Preclinical Studies
Recent preclinical studies have yielded promising insights regarding ZW191's efficacy. At the American Association for Cancer Research (AACR) Annual Meeting, data presented revealed that ZW191 exhibited marked anti-tumor activity compared to established benchmarks within FR?-expressing models. Additionally, it demonstrated favorable tolerability in cynomolgus monkeys at doses reaching 60 mg/kg.
Details on Trial Structure and Expectations
The Phase 1 study is structured into two parts, aiming to recruit 145 adult patients globally. The trial will take place across various sites in North America, Europe, and Asia-Pacific. Part one focuses on the safety and tolerability of ZW191 through dose escalation in identified patients, while part two will center on assessing the potential anti-tumor activities of the study drug.
Innovative Therapeutic Solutions
ZW191's target—folate receptor-?—is a critical protein in several tumor contexts. The design behind ZW191 emphasizes an exceptional capability to deliver a proprietary payload known as ZD06519, a topoisomerase-1 inhibitor, straight into the cancer cells, enhancing therapeutic outcomes.
About Zymeworks and Its Future Prospects
Zymeworks is steadfast in its mission to redefine cancer treatment through the discovery and development of multifaceted biotherapeutics. The company utilizes its Azymetric™ technology to create novel therapeutics, exemplified by zanidatamab, a bispecific antibody currently in multiple global trials for HER2-expressing cancers.
Collaborative Efforts and Global Reach
Through strategic partnerships, including collaborations with BeiGene and Jazz Pharmaceuticals, Zymeworks ensures the efficient development and commercialization of zanidatamab across various territories. Moreover, applications for accelerated approval of zanidatamab have been filed with regulatory bodies in the U.S. and China, which, if successful, could lead to significant breakthroughs in treating HER2-positive cancers.
Contact Information for Interested Parties
For those eager to learn more about Zymeworks' innovative initiatives, inquiries can be directed to:
Investor Inquiries:
Shrinal Inamdar, Director, Investor Relations
(604) 678-1388
ir@zymeworks.com
Media Inquiries:
Diana Papove, Senior Director, Corporate Communications
(604) 678-1388
media@zymeworks.com
Frequently Asked Questions
What is ZW191?
ZW191 is an antibody-drug conjugate designed to treat advanced solid tumors expressing folate receptor-?. It aims to improve patient outcomes in cancers like ovarian and lung cancer.
What does the Phase 1 clinical trial involve?
The Phase 1 trial consists of two parts; the first part explores ZW191's safety and tolerability, while the second part evaluates its potential anti-tumor activity in patients.
How does ZW191 work?
ZW191 specifically targets folate receptor-? present in certain tumors, delivering the payload ZD06519 directly into cancer cells to promote their destruction.
What are the goals of Zymeworks?
Zymeworks aims to develop innovative biotherapeutics to address and improve treatments for cancers and other challenging diseases, potentially revolutionizing existing treatment approaches.
How can investors learn more about Zymeworks?
Investor inquiries can be directed to Shrinal Inamdar via email at ir@zymeworks.com for more detailed information on Zymeworks’ progress and opportunities.
